Avalo Therapeutics Inc (AVTX)

$15.76 +0.96 (6.49%)
Market Cap 273.99M
Revenue (ttm) 440,000.00
Net Income (ttm) -35.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,984.09%
Debt to Equity Ratio 0.00
Volume 332,300
Avg Vol 342,822
Day's Range N/A - N/A
Shares Out 18.51M
Stochastic %K 39%
Beta 0.84
Analysts Strong Sell
Price Target $35.86

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 522 8707
Address:
540 Gaither Road, Suite 400, Rockville, United States
Trapjaw
Trapjaw Jan. 22 at 3:08 PM
$AVTX trend
0 · Reply
Trapjaw
Trapjaw Jan. 21 at 5:50 PM
$AVTX 🙏
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 12:58 AM
$AVTX Current Stock Price: $15.03 Contracts to trade: $15 AVTX Feb 20 2026 Call Entry: $0.50 Exit: $0.65 ROI: 30% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DragonAlgo
DragonAlgo Jan. 15 at 6:07 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Jan. 14 at 10:48 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 2:30 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
Trident1014
Trident1014 Jan. 9 at 1:18 PM
$AVTX Playing the $15 to $20 range is money. One of these days, it's not going to come back to $15 though.
0 · Reply
Trapjaw
Trapjaw Jan. 9 at 9:53 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Jan. 7 at 2:43 PM
$AVTX back to 18🙏
0 · Reply
Trapjaw
Trapjaw Jan. 5 at 5:22 PM
$AVTX
0 · Reply
Latest News on AVTX
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025, 4:30 PM EST - 2 months ago

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 6, 2025, 7:00 AM EST - 2 months ago

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 2 months ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 29, 2025, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Oct 1, 2025, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Sep 22, 2025, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Aug 18, 2025, 8:30 AM EDT - 5 months ago

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 7, 2025, 7:00 AM EDT - 6 months ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Jun 18, 2025, 7:00 AM EDT - 7 months ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025, 7:00 AM EDT - 9 months ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 9 months ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 26, 2025, 7:00 AM EDT - 10 months ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Mar 25, 2025, 3:20 PM EDT - 10 months ago

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Avalo Reports 2024 Financial Results and Recent Business Updates

Mar 20, 2025, 7:00 AM EDT - 11 months ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Jan 2, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 24, 2024, 4:01 PM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 17, 2024, 7:30 AM EDT - 1 year ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 7:30 AM EDT - 1 year ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Apr 1, 2024, 6:02 AM EDT - 1 year ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 29, 2024, 4:01 PM EDT - 1 year ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Avalo Completes Divestiture of AVTX-800 Series

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Avalo to Participate in SVB Securities Therapeutics Forum

Jul 6, 2023, 4:01 PM EDT - 2 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Avalo to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the Jefferies Healthcare Conference

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 22, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 15, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023, 4:01 PM EDT - 2 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 3 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 7:00 AM EST - 3 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 9:54 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Jan 17, 2023, 7:00 AM EST - 3 years ago

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Trapjaw
Trapjaw Jan. 22 at 3:08 PM
$AVTX trend
0 · Reply
Trapjaw
Trapjaw Jan. 21 at 5:50 PM
$AVTX 🙏
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 12:58 AM
$AVTX Current Stock Price: $15.03 Contracts to trade: $15 AVTX Feb 20 2026 Call Entry: $0.50 Exit: $0.65 ROI: 30% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DragonAlgo
DragonAlgo Jan. 15 at 6:07 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Jan. 14 at 10:48 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 2:30 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-02-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $2.10 Stop: $1.51 TP1: $2.73 TP2: $3.57 TP3: $5.04 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
Trident1014
Trident1014 Jan. 9 at 1:18 PM
$AVTX Playing the $15 to $20 range is money. One of these days, it's not going to come back to $15 though.
0 · Reply
Trapjaw
Trapjaw Jan. 9 at 9:53 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Jan. 7 at 2:43 PM
$AVTX back to 18🙏
0 · Reply
Trapjaw
Trapjaw Jan. 5 at 5:22 PM
$AVTX
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 4:38 AM
$AVTX Current Stock Price: $18.99 Contracts to trade: $20 AVTX Jan 16 2026 Call Entry: $1.08 Exit: $1.69 ROI: 57% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Trapjaw
Trapjaw Dec. 18 at 2:39 PM
$AVTX
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 9:39 AM
Mizuho has adjusted their stance on Avalo Therapeutics ( $AVTX ), setting the rating to Outperform with a target price of 39.
0 · Reply
Trapjaw
Trapjaw Dec. 17 at 4:45 PM
$AVTX
0 · Reply
Trapjaw
Trapjaw Dec. 17 at 3:24 PM
$AVTX nice
0 · Reply
Trapjaw
Trapjaw Dec. 16 at 8:14 PM
$AVTX why ist this stock so unpopular under re tail
0 · Reply
Trapjaw
Trapjaw Dec. 16 at 5:13 PM
$AVTX resu lts
0 · Reply
Trapjaw
Trapjaw Dec. 16 at 5:12 PM
$AVTX imagine positive
0 · Reply
Trapjaw
Trapjaw Dec. 16 at 4:27 PM
$AVTX nice
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 2:11 PM
$AVTX Share Price: $17.72 Contract Selected: Apr 17, 2026 $20 Calls Buy Zone: $3.29 – $4.06 Target Zone: $6.21 – $7.60 Potential Upside: 78% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
mku
mku Dec. 12 at 9:45 AM
$AVTX Got on the hype train 2 years ago and got in at 31 dollars. Then forgot about it. Good to see it going up again. Hopefully reaches my average some day 😂
0 · Reply
Trapjaw
Trapjaw Dec. 11 at 3:34 PM
$AVTX 21 today
0 · Reply